Tesaro Doubles Off Ovarian Cancer Drug Trial Results

Tesaro Inc TSRO shares are trading higher by $41.70 at $78.91 in Wednesday's session. The catalyst for the torrid rally is the announcement that the Phase 3 Nova trial of Niraparib achieved its primary endpoint of progression-free survival.

Related Link: TESARO Spikes 110% After Drug Significantly Improved Progression-Free Survival For Ovarian Cancer Patients

The rally from the pre-market session has carried over big time into the regular session. Investors didn't hesitate to go long the issue even after a $30+ higher open. In fact, it dipped only $0.28 to $68.50 before continuing its move higher. So far, it has reached $79.80 and is not far off that level.

Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: TechnicalsIntraday UpdateMoversTrading Ideas
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!